Publications by authors named "Larry Copeland"

Claim this Profile
P
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).
Brian M Slomovitz, S John Weroha, Wei Deng, Hye Sook Chon, Vivek Podder, Larry J Copeland

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapy.
Molly Morton, Julia Chalif, Jessica Sciuva, Jessica Fulton, Reed O'Connor, Larry J Copeland

Gynecol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in prospectively collected patient-reported outcomes among women with incident endometrial cancer.
Jennifer A Sinnott, Elaheh Torkashvand, Caitlin E Meade, Ritu Salani, Monica Hagan Vetter, Larry J Copeland

J Cancer Surviv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory evaluation of immunotherapy response and medication use in endometrial and cervical carcinoma.
Julia Chalif, Molly Morton, Eric McLaughlin, Anna Gonzalez, Jessica Fulton, Larry J Copeland

Gynecol Oncol Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer.
Mario M Leitao, Kristin L Bixel, Dana Meredith Chase, Allison Quick, Colleen McCormick, Larry J Copeland

Int J Gynecol Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
Quinn Kistenfeger, Paulina J Haight, Monica Levine, Heather Wang, Floor J Backes, Larry J Copeland

Gynecol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc's Scholar Career Development Award and New Investigator Program.
Angeles Alvarez Secord, Ronald D Alvarez, Leslie M Randall, Robert S Mannel, David G Mutch, Larry J Copeland

Int J Gynecol Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of readability of gynecologic cancer clinical trials literature at National Cancer Institute-designated Comprehensive Cancer Centers.
Julia Chalif, Wafa Khadraoui, John L Hays, Larry J Copeland, Roberto Vargas

Int J Gynecol Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of readability of informed consent forms of gynecologic cancer clinical trials: A (Potential) barrier to enrollment?
Wafa K Khadraoui, Quinn M Kistenfeger, Molly Herman, Floor Backes, Larry J Copeland

Gynecol Oncol Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining "enlarged" sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?
Paulina Haight, Caroline Bilbe, Courtney Riedinger, Floor Backes, Kristin Bixel, Larry Copeland

Gynecol Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.
Ignace Vergote, Larry J Copeland, Toon Van Gorp, Annouschka Laenen, Giovanni Scambia

Eur J Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Larry J Copeland

Future Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial.
Jyoti Mayadev, Dmitriy Zamarin, Wei Deng, Heather A Lankes, Giulio Pesci, Larry Copeland

Nat Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.
Whitney S Graybill, Beatriz Pardo Búrdalo, David M O'Malley, Ignace Vergote, Bradley J Monk, Larry J Copeland

Int J Gynecol Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
Courtney J Riedinger, David A Barrington, Christa I Nagel, Wafa K Khadraoui, Paulina J Haight, Larry J Copeland

Gynecol Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
Courtney J Riedinger, David A Barrington, Christa I Nagel, Wafa K Khadraoui, Paulina J Haight, Larry J Copeland

Gynecol Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Monica D Levine, Heather Wang, Bhargavi Sriram, Ambar Khan, Leigha Senter, Larry J Copeland

Gynecol Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study.
John K Chan, Chunqiao Tian, Joshua P Kesterson, Ken Y Lin, Kathleen Darcy, Larry Copeland

Gynecol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
Paulina J Haight, Quinn Kistenfeger, Courtney J Riedinger, Wafa Khadraoui, Floor J Backes, Larry J Copeland

Gynecol Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Sandro Pignata, Michael Bookman, Jalid Sehouli, Austin Miller, Richard T Penson, Larry J Copeland

Gynecol Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?
Molly Morton, Eric M McLaughlin, Corinne A Calo, Michelle Lightfoot, Kristin L Bixel, Larry J Copeland

Gynecol Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mansoor R Mirza, Dana M Chase, Brian M Slomovitz, René dePont Christensen, Zoltán Novák, Larry J Copeland

N Engl J Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
Monica D Levine, David A Barrington, Caitlin E Meade, Sydney M Lammers, Eric M McLaughlin, Larry J Copeland

Gynecol Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FIGO IVB vaginal cancer with non-contiguous rectal metastasis treated with definitive chemoradiation: A case report.
Marie Fort, Alexander Yaney, Larry Copeland, Allison Quick

Gynecol Oncol Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Monica D Levine, David M O'Malley, Paulina J Haight, Leigha Senter, Vincent Wagner, Larry J Copeland

Gynecol Oncol Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis